Wells Fargo & Company Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its price target dropped by Wells Fargo & Company from $125.00 to $94.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 20.14% from the company’s current price.

Several other research analysts also recently weighed in on the company. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. UBS Group decreased their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday. Royal Bank Of Canada boosted their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Mizuho reduced their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Truist Financial lowered their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $110.86.

Boston Scientific Stock Performance

Shares of BSX stock traded up $2.74 during mid-day trading on Thursday, reaching $78.24. 22,271,856 shares of the company’s stock traded hands, compared to its average volume of 15,930,081. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm has a 50 day moving average price of $94.37 and a two-hundred day moving average price of $99.13. The firm has a market capitalization of $115.99 billion, a PE ratio of 41.86, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. Boston Scientific has a 12 month low of $74.86 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the firm posted $0.70 EPS. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Steph & Co. acquired a new stake in shares of Boston Scientific in the 3rd quarter worth $25,000. Financial Consulate Inc. purchased a new position in shares of Boston Scientific during the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth $26,000. Finally, United Community Bank boosted its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat expectations — EPS $0.80 vs. $0.78 consensus and revenue $5.29B (+15.9% year/year), with margin improvements and solid organic growth. This underpins the company’s longer-term growth story. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Long-term research coverage highlights BSX as a growth stock based on Zacks style scores — a supportive narrative for buy-and-hold investors focused on medical-device secular trends. Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Multiple analysts cut price targets after the print but largely kept buy/overweight ratings — signaling confidence in the franchise but tempered near-term estimates. The headline impact is mixed: sells on caution, but continued analyst support limits downside. Boston Scientific Analysts Cut Their Forecasts Following Q4 Results
• Negative Sentiment: Management’s modest FY2026 revenue and EPS guidance, plus softer-than-expected electrophysiology sales, sparked a large intra-day sell-off (stock plunged double-digits after the report) as investors reset growth expectations. That guidance concern remains the primary driver of recent weakness. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Elevated bearish activity and insider selling add pressure — options flow showed a spike in put buying around the print, and CEO Michael Mahoney disclosed a large sale of ~160,901 shares, which can amplify short-term negative sentiment. Insider Selling: Boston Scientific (NYSE:BSX) CEO Sells 160,901 Shares of Stock

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.